NASDAQ:PETV PetVivo 8/13/2026 Earnings Report $0.77 +0.00 (+0.20%) As of 09:30 AM Eastern Profile PetVivo EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/APetVivo Revenue ResultsActual RevenueN/AExpected Revenue$0.01 millionBeat/MissN/AYoY Revenue GrowthN/APetVivo Announcement DetailsQuarterDate8/13/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile PetVivo Earnings HeadlinesPetVivo Holdings Inc.July 20 at 12:05 PM | marketwatch.comPetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary RecordJuly 14, 2026 | globenewswire.comSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.July 21 at 1:00 AM | TradeSmith (Ad)PetVivo (NASDAQ:PETV) Stock Price Down 5% - Here's WhyJuly 14, 2026 | americanbankingnews.comPetVivo Holdings Inc (PETV) Q4 2026 Earnings Call Highlights: Navigating Growth Amidst ChallengesJuly 2, 2026 | finance.yahoo.comPetVivo Holdings, Inc.: PetVivo Reports Financial and Operational Results for Fiscal 2026June 30, 2026 | finanznachrichten.deSee More PetVivo Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PetVivo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetVivo and other key companies, straight to your email. Email Address About PetVivoPetVivo (NASDAQ:PETV), Inc., headquartered in Ormond Beach, Florida, is a regenerative biomedical technology company specializing in veterinary applications. The company's core focus is on developing and commercializing sustained-release intra-articular therapies for animals through its proprietary RediVet injectable micro-plug system. This biodegradable polymer platform is designed to provide controlled release of therapeutic agents directly into joints, targeting osteoarthritis and related inflammatory conditions in companion and performance animals. PetVivo’s lead product, the RediVet-40 system, has been evaluated in proof-of-concept trials involving canine patients with osteoarthritis. The platform offers potential benefits over traditional injectable treatments by extending therapeutic exposure and reducing dosing frequency. PetVivo is also exploring additional development pathways for equine and other species, leveraging its delivery technology to address unmet medical needs in veterinary orthopedics. Founded in 2015, PetVivo has cultivated collaborations with veterinary clinics and academic research institutions across North America to advance clinical studies and support product adoption. The company maintains a portfolio of patents covering its micropellet delivery technology, underlying formulations and methods of use, underscoring its commitment to proprietary innovation in animal health and regenerative medicine. PetVivo’s leadership team combines expertise in biomedical engineering, veterinary science and commercial product development. Through ongoing research and strategic partnerships, the company aims to expand its product pipeline and establish new channels for bringing advanced regenerative therapies to veterinary healthcare providers and their patients.View PetVivo ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity?IBM Just Had Its Worst Day Ever—What Earnings Must ProveMeta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
